Literature DB >> 2405059

Reduced concentrations of IgG antibodies to Pneumocystis carinii in HIV-infected patients during active Pneumocystis carinii infection and the possibility of passive immunisation.

S M Burns1, J A Read, P L Yap, R P Brettle.   

Abstract

The relationship between Pneumocystis carinii antibody concentrations and acute Pneumocystis infection was investigated by testing sequential samples of serum from HIV antibody-positive patients with respiratory symptoms and HIV-negative immunocompromised patients by means of an indirect immunofluorescence assay for specific IgG antibodies to P. carinii. Loss of circulating antibody at the time of active Pneumocystis infection was observed in five patients with proven infection. Three others showed recovery of antibody coinciding with treatment and clinical recovery from infection. Concentrations of specific IgG antibody against P. carinii were measured in 40 blood donors and in six different batches of an intravenous immunoglobulin (IV Ig) preparation. Titres greater than 128 were found in the IV Ig batches examined. The use of IV Ig, either alone or in conjunction with other therapeutic agents, should therefore be considered in patients suffering from acute infection with P. carinii.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405059     DOI: 10.1016/s0163-4453(90)92280-x

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  10 in total

1.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

2.  Decreased production of local immunoglobulin A to Pneumocystis carinii in bronchoalveolar lavage fluid from human immunodeficiency virus-positive patients.

Authors:  A Jalil; P Moja; C Lambert; M Perol; L Cotte; J M Livrozet; A Boibieux; J M Vergnon; F Lucht; R Tran; C Contini; C Genin
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

3.  Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region.

Authors:  Q Mei; R E Turner; V Sorial; D Klivington; C W Angus; J A Kovacs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice.

Authors:  J B Roths; C L Sidman
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

5.  Predicting in-hospital outcome in HIV-associated Pneumocystis carinii pneumonia.

Authors:  T Bauer; S Ewig; E Hasper; J K Rockstroh; B Lüderitz
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

6.  Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Authors:  K Daly; J Koch; N Respaldiza; C de la Horra; M A Montes-Cano; F J Medrano; J M Varela; E J Calderon; P D Walzer
Journal:  Clin Microbiol Infect       Date:  2009-03-21       Impact factor: 8.067

7.  Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients.

Authors:  Kpandja Djawe; Laurence Huang; Kieran R Daly; Linda Levin; Judy Koch; Alexandra Schwartzman; Serena Fong; Brenna Roth; Anuradha Subramanian; Katherine Grieco; Leah Jarlsberg; Peter D Walzer
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

8.  Antibody response to Pneumocystis jirovecii major surface glycoprotein.

Authors:  Kieran R Daly; Laurence Huang; Alison Morris; Judy Koch; Kristina Crothers; Linda Levin; Shary Eiser; Supriya Satwah; Patricia Zucchi; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

9.  Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.

Authors:  Robert J Blount; Leah G Jarlsberg; Kieran R Daly; William Worodria; J Lucian Davis; Adithya Cattamanchi; Kpandja Djawe; Alfred Andama; Judith Koch; Peter D Walzer; Laurence Huang
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

10.  Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci.

Authors:  Kieran R Daly; Judy Koch; Linda Levin; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.